ADAR1 Capital Management, LLC
Q3 2025 13F-HR Holdings
Net value change ($000)
+412,485
(63.3%)
New positions
47
Sold out positions
43
Turnover %
12.1%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2025
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ABVX | 91,189 | 388.1% |
| ROIV | 28,775 | 131.6% |
| IMVT | 27,576 | 322.1% |
| 89bio, Inc. | 22,461 | 261.1% |
| SPY | 22,414 | 159.9% |
| KROS | 13,311 | 18.5% |
| PTGX | 13,311 | 25.4% |
| SEPN | 13,175 | 147.1% |
| LXEO | 9,589 | 1644.8% |
| CYTK | 9,286 | 48.3% |
Top Reduces (Value $000, Stocks/ETFs)
| Sage Therapeutics, Inc. | -6,581 | -100.0% |
| PRTA | -6,148 | -30.0% |
| Verve Therapeutics, Inc. | -5,267 | -100.0% |
| HELIX ACQUISITION CORP II | -4,701 | -100.0% |
| SHY | -4,420 | -100.0% |
| ARDX | -3,587 | -100.0% |
| CGON | -3,578 | -26.3% |
| Third Harmonic Bio, Inc. | -3,382 | -100.0% |
| CNTA | -2,599 | -66.6% |
| ALEC | -2,413 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
54,738
(5.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|